2. Allows optimal use of limited community resource
First animal to human transfusion on 1667 by Denis
Landsteiner description of blood group on 1901
Direct transfusion by means of arterio-venous anastomosis on 1917
Introduction
Transfusing only the portion of the blood
needed by the patient is called blood
component therapy
3. Red blood cell Oxygenation of tissues
Platelets Prevention or cessation of bleeding
Fresh frozen plasma Cessation of bleeding
Cryoprecipitate Cessation of bleeding
Cryoprecipitate-poor plasma Plasma exchange
Granulocytes Treatment of infection
Frozen blood cells Storage of rare blood
Leukocyte-depleted red cells Prevention of reaction and certain diseases
Component and Medical use
8. Anticoagulants prevent blood clotting
Preservatives provide nutrients for cells
Anticoagulants - Preservative Solutions
9. Anticoagulants
CPD CPD-A1
Storage time 21 days 35 days
Temperature 1-6 °c 1-6 °c
Slows glycolytic activity
Adenine None Substrate for ATP synthesis
Volume 450 +/- 10%
Dextrose Supports ATP generation by glycolytic pathway
Citrate Prevents coagulation by binding calcium
10. Add additive solution to RBCs which consists of:
• Saline
• Adenine
• Glucose
• Mannitol
Extends storage to 42 days
Final hematocrit approximately 66%
Additive Solution
11. Affects oxygen dissociation curve
pH drops
↓ 2,3-DPG
Once transfused RBCs regenerate ATP , 2,3-DPG
Few functional platelets present
Viable (living) RBCs decrease
Changes in stored blood
13. Modified by
• Irradiation
• Leukoreduction (filters)
• Washing ( saline or saline-anticoagulant sol)
Modifications of blood component
14. Blood/ Start infusion Complete infusion
blood product
Whole blood/ within 30 min. of within 4 hour
red cells removing pack (less in high
ambient temperature)
Platelet immediately within 20 min
concentrates
FFP within 30 min within 20 min
15. Plasma derivatives are fractionated from large volumes of
plasma in large industrial units
Ex: Albumin, intravenous gamma globulin, Factor 8 etc..
Difference between blood
component and plasma
derivatives?
16. Types
Whole blood
Packed red blood cells
RED CELL TRANSFUSIONS
Used to increase the haemoglobin level
in patients with anemia or to replace
losses after acute bleeding episodes
17. Comparison between Whole blood and PRBC
Parameter Whole blood Packed red cells
Volume 350 – 450 ml 250 – 300 ml
Increment in Hb 1 -1.5 gm/dl 1 -1.5 gm/dl
Red cell mass /ml Same as PRBC Same as WB
Viable platelets No No
Labile factors No No
Plasma citrate ++++ +
Allergic reactions ++++ +
FNHTR ++++ +
Waste of components Yes No
18. Volume – 225 to 350 ml
Anticoagulant used – citrate phosphate dextrose adenine
Shell life ( with additive solutions)- 35 to 42 days
Stored at 4°c
Must be ABO compatible,
↑Hb One unit by 1 g/dl or ↑Hct 3%
Adverse reactions can be prevented by leukoreduction
and irradiation
PACKED RED BLOOD CELLS
19. Whole blood :
Acute and massive loss of blood where volume replacement is
required
Packed RBC :
Anemia with Hb ≤7.0 gm/dl
To increase the oxygen carrying capacity
Indications
Exceptions to this rule are
• Symptomatic myocardial ischemia with Hb <10gm/dl.
• Trauma or on-going blood loss where strict cut-off may not be possible
20. Loss of Total blood volume (TBV) :
TBV - 30-40%
• Rapid volume replacement
• RBC transfusion likely needed
TBV - >40%
• Life-threatening bleeding
• Requires rapid volume replacement
• Requires RBC transfusion
Indication in Acute Blood Loss
21. Treat the underlying cause (e.g. iron,folate,B12)
Try EPO trial if the patient can be observed rather than treated
immediately
Indication in Chronic Blood Loss
Hb >10g/dl, rarely needed
Hb <6g/dl, usually needed
Hb 6-10g/dl and Co-morbid Conditions
22. • 20% blood volume loss can do well without transfusion
• Change in vitals signs not due to anaesthesia
• Decreased Urine Output
• Estimated blood loss > 1000 ml
Indication in Intraoperative Usage
Whether patient requires transfusion or not should be
decided based upon clinical condition, not solely by the
haemoglobin level
23. FFP – plasma is separated and stored at -18 to -30°c within 8
hours of collection
PF24- separated within 24 hours of collection.
(Both of above products can be stored upto one year)
PLASMA COMPONENTS
• Thawed plasma – after plasma is thawed it can be kept in
refrigerator(1-6 ̊C) for 4 days.
• Liquid plasma - plasma that has never been frozen. Expire in 5 days.
• Solvent/detergent plasma - treatment with viral inactivating
agents prior to freezing.
24. Method of collection: whole blood or plasma by apheresis technique
Standard unit : 200-250 ml.
Dosage and infusion rate
o Infused in 1-2 hour, in neonate 15ml/kg/hr
o in volume overload patients- 1ml/kg/hr
Due to the short half-life of coagulation factors, frozen as FFP within
8 hours of collection of blood
FRESH FROZEN PLASMA (FFP)
25. INR 1.6 with bleeding
INR 1.6 and patients about to go to undergo an invasive procedure,
Therapeutic exchange
Major bleeding associated with warfarin anticoagulation or vitamin
K deficiency
Deficiency of multiple coagulation factors , Ex: Liver disease, DIC
Factor replacement for rare inherited coagulation factor disorders
Indications
26. FFP is thawed at 4°c & resulting precipitate is separated
from plasma by centrifugation
Contains factor 8(100 units), factor 9, fibrinogen(200mg),
fibronectin and von willebrand factor in each unit
Storage in freezer for one year.
CRYOPRECIPITATE
(cryoprecipitated antihaemophilic factor)
27. • Deficiencies of factor 8 and fibrinogen
• Fibrinogen 100 and the patient is bleeding or about to undergo
an invasive procedure
• Massive bleeding
• Can be used in uremic bleeding, which is not responding to
other measures.
Indications
28. Types
1. Random donor platelets (pooled platelets)
2. Single donor platelet (apheresis platelets)
PLATELET TRANSFUSION
29. One unit of platelet is isolated from every unit of donated blood by
centrifuging
4 to 6 units of pooled platelets are required in single setting to raise
the platelet level
Advantages : Low cost, easy collection and processing
Disadvantages : Exposure to multiple donors in single transfusion
and risk of infection
Random donor platelets
(Pooled platelets)
30. Platelets are collected from a single donor in blood bank over two
hour Pheresis procedure
Platelets and some white cells are removed while red cells and
plasma are returned back to donor
One unit of SDP is equivalent to six units of RDP
Advantage : Here recipient is exposed to only single donor
Single donor platelet
(Apheresis platelets)
31. Storage :
At 20 ̊C- 24 ̊C with continuous gentle
agitation
Shell life :
only 5 days, longer storage increases
risk of bacterial contamination
Platelet – cont.
32. [To treat active bleeding]
Count must be kept above 50,000/mm3 in most bleeding situations
In DIC and central nervous system bleeding , cut off is 1,00,000/mm3
Bleeding on anti platelet medication
Indications
(Therapeutic)
33. 1. Preparation for an invasive procedure :
• Neurosurgery or Ocular surgery : 1,00,000/mm3
• Major surgery : 50,000/mm3
• Endoscopic procedures : 50,000/mm3 for therapeutic
: 20,000/mm3 for diagnostic
• Central line placement : 20,000/mm3
• Lumbar puncture : 40,000/mm3 to 50,000/mm3
• Epidural anaesthesia : 80,000/mm3
• Bone marrow aspiration : 20,000/mm3
(Can be done with lower counts with applying pressure at site of procedure)
Indications
(Prophylactic)
[To prevent spontaneous bleeding]
34. 2. Prevention of spontaneous bleeding
- Afebrile patients (Bone marrow suppression) : 10,000/mm3
- Febrile or septic patients : 30,000/mm3
- ITP, TTP or HIT : Transfusion is indicated only if they bleed
- Haematological malignancies and chemotherapy : 10,000 – 20,000/mm3
Indications – cont..
35. Dosage of platelets
- One unit of SDP or 4-6 units of RDP over a period of 20-30 minutes
- Increases platelet count by approximately 30,000/mm3
Platelet – cont.
Platelets express ABO and HLA type 1 class antigens , usually
compatible transfusions appear to cause a greater count increment
in patients
36. Method of collection : by apheresis technology , after
granulocytes are stimulated by dexamethasone and G-CSF
To be transfused within few hours of collection
Shell life – 24 hours at room temperature
Indications :
- Neutropenia from chemotherapy or transplantation
- Aplastic anaemia
- Neonatal sepsis
- Chronic granulomatous disease
GRANULOCYTE TRANSFUSION
37. Features of PBM
- Evidence based guidelines for transfusion indication and dose
- Physician education and monitoring
Patient Blood Management (PBM)
PBM is a multidisciplinary approach to
improve patient outcome using evidence based
strategies in patients who may need
transfusion
38. - Preoperative anemia evaluation and management
- Intraoperative and postoperative autologous salvage
- Intraoperative normovolemic hemodilution
- Point of care hemostasis testing
- Use of hemostatic agents
- Limiting phlebotomy blood loss for laboratory testing
Features of PBM – cont..
41. 1. Acute hemolytic transfusion reaction :
• Recipient has preformed antibodies that lyse donor erythrocytes
• ABO isoagglutinins are responsible for the majority of these reactions
Clinical Features : Hypotension, tachypnoea, tachycardia, fever chills,
hemoglobinemia, hemoglobinuria, chest or flank pain, discomfort at the
infusion site, renal dysfunction
Work up : Serum haptogloblin, Serum LDH, Indirect bilirubin
Transfusion Reaction – Immune mediated
42. Management :
STOP blood transfusion immediately
Diuresis- Furosemide or Mannitol
Subject post transfusion blood to coomb’s test
Transfusion Reaction – Immune mediated Cont..
2. Delayed hemolytic transfusion reactions:
- Occurs in patients previously sensitized to donor allo-antigens.
43. Immunohematology and other testing in DSHTR
DSHTR (Delayed serologic/hemolytic transfusion reactions)
DAT (Direct Anti-globulin Test)
Negative Positive
Ongoing
hemolysis
not
suspected
No further testing
recommended
Ongoing
hemolysis
suspected
Perform eluate
Positive eluate:
• Antigen type units transfused – if unit
segment available
• Repeat immunohematology on
previous specimen – if available
Other
markers
of hemolysis
• LDH
• Total Bilirubin
• Direct Bilirubin
• Haptoglobin
Negative eluate:
No further testing
recommended
44. 3. Febrile Non-hemolytic Transfusion Reaction
Most frequent reaction
Chills and rigors and a rise in temperature >1°c
Diagnosis of exclusion
Antibodies directed against donor leukocyte and HLA antigens mediates
these reactions
Leukoreduction of blood products reduces the risk
Transfusion Reaction – Immune mediated Cont..
45. 4. Anaphylactic Reaction:
Symptoms and signs : Shortness of breath, coughing, nausea,
vomiting, hypotension, bronchospasm, loss of consciousness, respiratory
arrest and shock
Treatment :
o Stop the transfusion and maintain vascular access
o Epinephrine (0.5- 1 mL of 1 : 1000 dilution subcutaneously)
o Steroids in severe cases
Transfusion Reaction – Immune mediated Cont..
46. 5. Transfusion Associated Lung Injury (TRALI)
New ALI/ARDS occurring during or within six hours after blood product
administration
Anti HLA or
anti granulocyte Ab
in donor plasma
Recipient
WBC
Complement
activation
Pulmonary sequestration and
activation of neutrophils
Endothelial damage
Capillary leak in Lungs
TRALI
Transfusion Reaction – Immune mediated Cont..
47. Symptoms and signs :
Dyspnoea, hypotension, fever
Bilateral non-cardiogenic pulmonary edema, Pao2/FIo2 <300mmHg
Management :
Supportive
Avoid plasma transfusion from multiparous women and screening for anti-
HLA antibodies
A
L
I
Transfusion Reaction – Immune mediated Cont..
5. TRALI – cont..
48. 6. Transfusion Associated GVHD (TA-GVHD) :
Mediated by donor T lymphocytes that recognize host HLA antigens as
foreign and mount an immune response
Clinical features : Fever with characteristic Cutaneous eruption,
Diarrhoea and liver function abnormalities
Treatment :
o GVHD highly resistant to treatment with immunosuppressive therapies
o Irradiation of cellular components reduces the risk
Transfusion Reaction – Immune mediated Cont..
49. 7. Post-transfusion Purpura:
Thrombocytopenia 7-10 days after platelet transfusion
Common in women
Antibody react with both donor and recipient platelets
Antigen HPA-1a found on platelet glycoprotein receptor шa receptor
Avoid further transfusion
IV immunoglobulin or plasmapheresis can be tried
Transfusion Reaction – Immune mediated Cont..
50. 8. Allergic reaction:
Urticarial reaction are related to plasma protein found in
transfused components
Treatment :
o Stop transfusion and Administer antihistamines (diphenhydramine
50 mg orally or IM)
o Continue transfusion after symptom resolved
o Premedication with antihistamines can be tried when history of
transfusion reaction present
Transfusion Reaction – Immune mediated Cont..
51. 1. Fluid over load (TACO) :
o Clinical Features : Severe hypoxemia, Raised BP, Jugular
venous distension, Raised central venous pressure
o Diagnosis : CXR- pulmonary edema, cardiomegaly, distended
pulmonary artery, BNP – elevated >1.5
o Treatment : Upright posture, Supplemental oxygen, Diuresis
o Prevention : Slow transfusion rate, Transfuse in small volumes
Transfusion Reaction – Non-Immune mediated
52. 2. Hypothermia :
- Because of rapid transfusion of refrigerated (4 ̊c) or frozen (18 ̊c)
components can cause cardiac dysrhythmia by exposing SA node to cold
fluid
- can use in line warmer
3. Electrolyte toxicity :
Hyperkalemia - Neonate and renal failure patient at risk.
Use fresh or washed RBC
Hypocalcemia - In multiple transfusion
Inj. Calcium IV in separate line
Transfusion Reaction – Non-Immune mediated
53. 4. Iron overload :
o Common after 100 units of RBC transfusion
o Deferoxamine or Deferasirox can be used
5. Hypotensive reactions :
o Noted in patient on ACE inhibitors because of increased Bradykinin.
o BP returns to normal without intervention
6. Immunomodulation :
o Transfusion of allogenic blood is immunosuppressive
o Mediated by transfused leukocytes
o Leukocyte depleted cellular products cause less immunosuppression
Transfusion Reaction – Non-Immune mediated
54. The transmittable risks include:
o Hepatitis B, C, D
o Human T-cell lymphotropic viruses
(HTLV-1 & HTLV-2)
o HIV-1 & HIV-2
o Cytomegalovirus
o West Nile Virus
o Epstein-Barr virus
Transfusion Reaction
(Infectious complications)
o Malaria
o Syphilis
o Parvovirus B19
o Prions including
Creutzfeldt-Jakob and
variant
o Lyme Disease
55. Pre-transfusion: Informed consent, Temp, Pulse, BP, O2 saturation
During transfusion: Vitals after 15 min
Only 0.9% NS is compatible
Avoid RL and hypo/hypertonic solution
Avoid medication in same line, if possible avoid al-together
Post transfusion:
Check sign for any reaction
Vitals 4-6 hr after BT
Clinical aspect of BT
No transfusion is zero
risk event